白蛋白结合型PSMA配体:扩大治疗窗的意义
研究通过结构修饰白蛋白结合基团或插入PEG8连接子,制备四种三功能PSMA靶向小分子,在LNCaP荷瘤小鼠中比较组织动力学。177Lu-RPS-072的肿瘤AUC和肿瘤/肾脏AUC比显著优于既往小分子,肾脏活性降低,治疗指数提高,是靶向放射性配体治疗的有前景候选。
要点
- 白蛋白亲和力提高可延迟血液清除并改变肿瘤与肾脏摄取动力学。
- 177Lu-RPS-072的肿瘤AUC最高,肿瘤/肾脏AUC比为4.7±0.3。
- PEG8连接子延长可加速肾脏清除,但降低白蛋白亲和力。
核心结论
- 177Lu-RPS-072的肿瘤AUC和肿瘤/肾脏AUC比显著优于迄今在LNCaP模型中研究的小分子。
- RPS-072治疗指数提高,有潜力增加肿瘤递送剂量,是靶向放射性配体治疗的高度有前景候选。
研究设计与样本
- 制备四种结构相关的三功能PSMA靶向小分子,改变白蛋白结合基团或插入PEG8连接子。
- 化合物经68Ga和177Lu标记,在携带LNCaP异种移植瘤的雄性BALB/C nu/nu小鼠中测定组织动力学。
主要发现
- 每种化合物抑制PSMA的半数抑制浓度不超过10 nM。
- 白蛋白结合基团对PSMA亲和力影响极小,但使白蛋白亲和力改变一个数量级。
- 加入PEG8间隔基在每个案例中均削弱白蛋白亲和力。
- 177Lu-RPS-072(34.9±2.4 %ID/g)和177Lu-RPS-077(27.4±0.6 %ID/g)的摄取在注射后24小时增加,96小时洗脱不显著。
- 肿瘤AUC顺序为177Lu-RPS-072 > 177Lu-RPS-077 > 177Lu-RPS-063 > 177Lu-RPS-071;177Lu-RPS-072的肿瘤AUC与肾脏AUC比为4.7±0.3。
关键数值与推荐
- 所有化合物PSMA半数抑制浓度≤10 nM。
- 177Lu-RPS-072肿瘤摄取34.9±2.4 %ID/g,177Lu-RPS-077为27.4±0.6 %ID/g。
- 177Lu-RPS-072的肿瘤/肾脏AUC比为4.7±0.3。
临床怎么用
- RPS-072作为白蛋白结合型PSMA配体,可能通过提高肿瘤AUC和肿瘤/肾脏比来扩大治疗窗。
- 结构优化中需权衡白蛋白亲和力与连接子长度对肾脏清除的影响。
局限性
- 研究仅基于LNCaP异种移植小鼠模型,尚未在人体中验证。
- 原文未报告其他PSMA靶向放射性配体在PC3-PIP模型中的具体数值比较。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Despite significant gains in the treatment of metastatic castration-resistant prostate cancer by radioligands targeting prostate-specific membrane antigen (PSMA), 30% of patients never respond to therapy. One possible explanation is insufficient dose delivery to the tumor because of suboptimal pharmacokinetics. We have recently described RPS-063, a trifunctional ligand targeting PSMA with high uptake in LNCaP xenograft tumors but also in kidneys. We aimed to use structural modifications to increase the tumor-to-kidney ratio through increased albumin binding and tumor uptake and reduction of kidney activity. Methods: Four structurally related trifunctional PSMA-targeting small molecules were prepared by either varying the albumin-binding group or inserting a polyethylene glycol 8 linker into a common structure. The compounds were ranked by PSMA affinity and albumin affinity and were radiolabeled with 68Ga and 177Lu. Tissue kinetics were determined in male BALB/C nu/nu mice bearing LNCaP xenograft tumors. Results: Each of the compounds binds PSMA with a half-maximal inhibitory concentration of no more than 10 nM. The albumin-binding group had a minimal effect on PSMA affinity but changed albumin affinity by an order of magnitude. However, the addition of a polyethylene glycol 8 spacer weakened affinity for albumin in each case. Increased affinity for albumin corresponded with delayed blood clearance and modified uptake kinetics in the tumor and kidney. Uptake of 177Lu-RPS-072 (34.9 ± 2.4 %ID/g) and 177Lu-RPS-077 (27.4 ± 0.6 %ID/g) increased up to 24 h after injection, and washout by 96 h was not significant. As a result, the area under the curve (AUC) in the tumor was in the following order: 177Lu-RPS-072 > 177Lu-RPS-077 > 177Lu-RPS-063 > 177Lu-RPS-071. Increased linker length corresponded to more rapid clearance from kidneys. Consequently, the ratio of tumor AUC and kidney AUC was 4.7 ± 0.3 for 177Lu-RPS-072. Conclusion: The tumor AUC and tumor-to-kidney ratio of 177Lu-RPS-072 are significantly enhanced compared with any small molecule investigated in a LNCaP xenograft model to date. In comparison to other PSMA-targeting radioligands that have been evaluated in a PC3-PIP model, activity in kidneys is reduced and activity in tumors compares favorably when the different PSMA expression levels in LNCaP and PC3-PIP cells are considered. RPS-072 therefore exhibits an increased therapeutic index, shows the potential to increase the dose delivered to tumors, and is a highly promising candidate for targeted radioligand therapy.
引用
- Kelly JM, Amor-Coarasa A, Ponnala S, et al. Albumin-Binding PSMA Ligands: Implications for Expanding the Therapeutic Window. J Nucl Med. 2018. PMID: 30552199. doi:10.2967/jnumed.118.221150
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。